Allergan depression drugs have billion dollar potential, says Cantor Fitzgerald

Cantor Fitzgerald analyst Louise Chen believes Two of Allergan’s depression drugs in development, rapastinel and AGN-241751, have billions of dollars in peak sales potential. These two opportunities are still underappreciated by the Street, Chen tells investors in a research note. She expects positive data for these treatments but keeps a Neutral rating on Allergan shares with a $180 price target.

https://bit.ly/2MnGeeQ